The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 13, 2022
Filed:
Nov. 08, 2019
Medimmune Limited, Cambridge, GB;
Carl Hay, Gaithersburg, MD (US);
Kris Sachsenmeier, Gaithersburg, MD (US);
Erin Sult, Gaithersburg, MD (US);
Qihui Huang, Gaithersburg, MD (US);
Peter Pavlik, Gaithersburg, MD (US);
Melissa Damschroder, Gaithersburg, MD (US);
Li Cheng, Gaithersburg, MD (US);
Gundo Diedrich, Gaithersburg, MD (US);
Jonathan Rios-Doria, Gaithersburg, MD (US);
Scott Hammond, Gaithersburg, MD (US);
Ralph Minter, Cambridge, GB;
Steve Rust, Cambridge, GB;
Sandrine Guillard, Cambridge, GB;
Robert Hollingsworth, Gaithersburg, MD (US);
Lutz Jermutus, Cambridge, GB;
Nicholas Durham, Gaithersburg, MD (US);
Ching Ching Leow, Gaithersburg, MD (US);
Mary Antonysamy, Gaithersburg, MD (US);
James Geoghegan, Gaithersburg, MD (US);
Xiaojun Lu, Gaithersburg, MD (US);
Kim Rosenthal, Gaithersburg, MD (US);
MedImmune Limited, Cambridge, GB;
Abstract
The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.